InspireMD (NYSE:NSPR) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Several other equities research analysts have also recently issued reports on the company. Piper Sandler reissued an “overweight” rating and set a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Stock Down 1.9 %

Shares of NSPR opened at $2.64 on Friday. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The stock has a fifty day simple moving average of $2.73 and a two-hundred day simple moving average of $2.70. The company has a market capitalization of $68.86 million, a PE ratio of -3.52 and a beta of 0.98.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. As a group, equities analysts anticipate that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new stake in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.